Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: NNFA

This article was originally published in The Tan Sheet

Executive Summary

NNFA: Burton Kallman, PhD, National Nutritional Foods Association director of Science & Technology, will retire, effective Dec. 31. A 12-year veteran of NNFA, Kallman has been the association's first and only science director and twice has served as acting executive director. During his tenure, Kallman has been active in a number of issues central to NNFA, including consolidation of differing GMP regs, creation of the group's scientific advisory council and development of NNFA's iron supplement voluntary program. In testimony at an April meeting of the President's Commission on Dietary Supplement Labels, Kallman called for the use of a science-based rating system for supporting supplement health claims ("The Tan Sheet" May 13, p. 8). A successor will be named in the spring, NNFA says. A search is under way. Kallman will be named science director emeritus...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel